The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...
The US FDA has approved the first of its kind ketamine-based nasal spray which is supposed to act as a standalone therapy for ...
Johnson & Johnson (NYSE:JNJ), a global healthcare giant, continues to navigate a complex landscape of opportunities and ...
A ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression in the US.
Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral ...
On the company’s Q4 earnings call where an eyepopping $88.8 billion in full-year sales were revealed, leaders shifted focus ...